Assessing the Efficacy of Frexalimab in Managing Multiple Sclerosis
|
Reviewed by Dat Tien Nguyen, B.A, ScM.
Translated by Nhi Phuong Quynh Le, B.A |
Posted on March 29th, 2024
|
The interaction between CD40 and CD40L plays a pivotal role in immune system activation. In individuals with multiple sclerosis, elevated CD40L expression fosters a robust T-lymphocyte response, contributing to disease progression. Consequently, Frexalimab, an antibody designed to bind to CD40L and impede this interaction, holds promise in mitigating disease severity. A recent study evaluating the efficacy of Frexalimab in managing multiple sclerosis has been published in the New England Journal of Medicine.
The phase 2 clinical trial enrolled 125 participants diagnosed with multiple sclerosis according to the McDonald criteria, with a minimum of one relapse episode within the previous year. To determine the optimal dose level and route of administration, participants were randomly assigned to receive two active agent schedules along with a placebo. The high-dose group received 1200 mg of Frexalimab intravenously every 4 weeks, starting with a dose of 1800 mg, while the low-dose group received 300 mg subcutaneously every 2 weeks, starting with 600 mg. By the 12th week of the trial, gadolinium-contrast scanning revealed a significant reduction in nervous system lesion development with Frexalimab usage. Moreover, comparison between the two dose levels indicated that the high intravenous dose was more effective than the low subcutaneous dose. However, the researchers underscored the necessity for larger and longer trials to comprehensively evaluate Frexalimab's effectiveness.
The phase 2 clinical trial enrolled 125 participants diagnosed with multiple sclerosis according to the McDonald criteria, with a minimum of one relapse episode within the previous year. To determine the optimal dose level and route of administration, participants were randomly assigned to receive two active agent schedules along with a placebo. The high-dose group received 1200 mg of Frexalimab intravenously every 4 weeks, starting with a dose of 1800 mg, while the low-dose group received 300 mg subcutaneously every 2 weeks, starting with 600 mg. By the 12th week of the trial, gadolinium-contrast scanning revealed a significant reduction in nervous system lesion development with Frexalimab usage. Moreover, comparison between the two dose levels indicated that the high intravenous dose was more effective than the low subcutaneous dose. However, the researchers underscored the necessity for larger and longer trials to comprehensively evaluate Frexalimab's effectiveness.